Molecular Cancer Therapeutics: 11 (5)

Highlights

Highlights

Highlights of This Issue

Mol Cancer Ther May 1 2012 11 (5) 1049-1049;

Reviews

Reviews

Attacking a Nexus of the Oncogenic Circuitry by Reversing Aberrant eIF4F-Mediated Translation

Peter B. Bitterman and Vitaly A. Polunovsky

Mol Cancer Ther May 1 2012 11 (5) 1051-1061; DOI:10.1158/1535-7163.MCT-11-0530
Reviews

Immunotherapy of Cancer with 4-1BB

Dass S. Vinay and Byoung S. Kwon

Mol Cancer Ther May 1 2012 11 (5) 1062-1070; DOI:10.1158/1535-7163.MCT-11-0677

Therapeutic Discovery

Therapeutic Discovery

Quantitative Proteomic Profiling Identifies Protein Correlates to EGFR Kinase Inhibition

Kian Kani, Vitor M. Faca, Lindsey D. Hughes, Wenxuan Zhang, Qiaojun Fang, Babak Shahbaba, Roland Luethy, Jonathan Erde, Joanna Schmidt, Sharon J. Pitteri, Qing Zhang, Jonathan E. Katz, Mitchell E. Gross, Sylvia K. Plevritis, Martin W. McIntosh, Anjali Jain, Samir Hanash, David B. Agus and Parag Mallick

Mol Cancer Ther May 1 2012 11 (5) 1071-1081; DOI:10.1158/1535-7163.MCT-11-0852
Therapeutic Discovery

Hyperactivation of 4E-Binding Protein 1 as a Mediator of Biguanide-Induced Cytotoxicity during Glucose Deprivation

Junichi Matsuo, Yoshinori Tsukumo, Sakae Saito, Satomi Tsukahara, Junko Sakurai, Shigeo Sato, Hiromichi Kondo, Masaru Ushijima, Masaaki Matsuura, Toshiki Watanabe and Akihiro Tomida

Mol Cancer Ther May 1 2012 11 (5) 1082-1091; DOI:10.1158/1535-7163.MCT-11-0871
Therapeutic Discovery

Off-Target Function of the Sonic Hedgehog Inhibitor Cyclopamine in Mediating Apoptosis via Nitric Oxide–Dependent Neutral Sphingomyelinase 2/Ceramide Induction

Marisa Meyers-Needham, Jocelyn A. Lewis, Salih Gencer, R. David Sentelle, Sahar A. Saddoughi, Christopher J. Clarke, Yusuf A. Hannun, Haakan Norell, Telma Martins da Palma, Michael Nishimura, Jacqueline M. Kraveka, Zohreh Khavandgar, Monzur Murshed, M. Ozgur Cevik and Besim Ogretmen

Mol Cancer Ther May 1 2012 11 (5) 1092-1102; DOI:10.1158/1535-7163.MCT-11-0705
Therapeutic Discovery

Evading Pgp Activity in Drug-Resistant Cancer Cells: A Structural and Functional Study of Antitubulin Furan Metotica Compounds

Tam Luong Nguyen, Maria Rosaria Cera, Andrea Pinto, Leonardo Lo Presti, Ernest Hamel, Paola Conti, Rick Gussio and Peter De Wulf

Mol Cancer Ther May 1 2012 11 (5) 1103-1111; DOI:10.1158/1535-7163.MCT-11-1018
Therapeutic Discovery

JAK–STAT and JAK–PI3K–mTORC1 Pathways Regulate Telomerase Transcriptionally and Posttranslationally in ATL Cells

Osamu Yamada, Kohji Ozaki, Masaharu Akiyama and Kiyotaka Kawauchi

Mol Cancer Ther May 1 2012 11 (5) 1112-1121; DOI:10.1158/1535-7163.MCT-11-0850

Preclinical Development

Preclinical Development

Obatoclax Interacts Synergistically with the Irreversible Proteasome Inhibitor Carfilzomib in GC- and ABC-DLBCL Cells In Vitro and In Vivo

Girija Dasmahapatra, Dmitry Lembersky, Minkyeong P. Son, Hiral Patel, Derick Peterson, Elisa Attkisson, Richard I. Fisher, Jonathan W. Friedberg, Paul Dent and Steven Grant

Mol Cancer Ther May 1 2012 11 (5) 1122-1132; DOI:10.1158/1535-7163.MCT-12-0021
Preclinical Development

The Effect of Different Linkers on Target Cell Catabolism and Pharmacokinetics/Pharmacodynamics of Trastuzumab Maytansinoid Conjugates

Hans K. Erickson, Gail D. Lewis Phillips, Douglas D. Leipold, Carmela A. Provenzano, Elaine Mai, Holly A. Johnson, Bert Gunter, Charlene A. Audette, Manish Gupta, Jan Pinkas and Jay Tibbitts

Mol Cancer Ther May 1 2012 11 (5) 1133-1142; DOI:10.1158/1535-7163.MCT-11-0727
Preclinical Development

ERK Inhibition Overcomes Acquired Resistance to MEK Inhibitors

Georgia Hatzivassiliou, Bonnie Liu, Carol O'Brien, Jill M. Spoerke, Klaus P. Hoeflich, Peter M. Haverty, Robert Soriano, William F. Forrest, Sherry Heldens, Huifen Chen, Karen Toy, Connie Ha, Wei Zhou, Kyung Song, Lori S. Friedman, Lukas C. Amler, Garret M. Hampton, John Moffat, Marcia Belvin and Mark R. Lackner

Mol Cancer Ther May 1 2012 11 (5) 1143-1154; DOI:10.1158/1535-7163.MCT-11-1010
Preclinical Development

Triggering Fbw7-Mediated Proteasomal Degradation of c-Myc by Oridonin Induces Cell Growth Inhibition and Apoptosis

Hui-Lin Huang, Heng-You Weng, Lu-Qin Wang, Chun-Hong Yu, Qiao-Juan Huang, Pan-Pan Zhao, Jun-Zhi Wen, Hui Zhou and Liang-Hu Qu

Mol Cancer Ther May 1 2012 11 (5) 1155-1165; DOI:10.1158/1535-7163.MCT-12-0066
Preclinical Development

miRNA-29b Suppresses Prostate Cancer Metastasis by Regulating Epithelial–Mesenchymal Transition Signaling

Peng Ru, Robert Steele, Philip Newhall, Nancy J. Phillips, Karoly Toth and Ratna B. Ray

Mol Cancer Ther May 1 2012 11 (5) 1166-1173; DOI:10.1158/1535-7163.MCT-12-0100
Preclinical Development | Free Article

Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas

Gangadhara R. Sareddy, Binoj C. Nair, Vijay K. Gonugunta, Quan-guang Zhang, Andrew Brenner, Darrell W. Brann, Rajeshwar Rao Tekmal and Ratna K. Vadlamudi

Mol Cancer Ther May 1 2012 11 (5) 1174-1182; DOI:10.1158/1535-7163.MCT-11-0960
Preclinical Development

Multiple Antigenic Peptides Based on H-2K^b–Restricted CTL Epitopes from Murine Heparanase Induce a Potent Antitumor Immune Response In Vivo

Xu-Dong Tang, Guo-Zhen Wang, Jun Guo, Mu-Han Lü, Chuan Li, Ning Li, Ya-Ling Chao, Chang-Zhu Li, Yu-Yun Wu, Chang-Jiang Hu, Dian-Chun Fang and Shi-Ming Yang

Mol Cancer Ther May 1 2012 11 (5) 1183-1192; DOI:10.1158/1535-7163.MCT-11-0607

Molecular Medicine in Practice

Molecular Medicine in Practice

Cotargeting MAPK and PI3K Signaling with Concurrent Radiotherapy as a Strategy for the Treatment of Pancreatic Cancer

Terence M. Williams, Athena R. Flecha, Paul Keller, Ashwin Ram, David Karnak, Stefanie Galbán, Craig J. Galbán, Brian D. Ross, Theodore S. Lawrence, Alnawaz Rehemtulla and Judith Sebolt-Leopold

Mol Cancer Ther May 1 2012 11 (5) 1193-1202; DOI:10.1158/1535-7163.MCT-12-0098
Molecular Medicine in Practice

High TUBB3 Expression, an Independent Prognostic Marker in Patients with Early Non–Small Cell Lung Cancer Treated by Preoperative Chemotherapy, Is Regulated by K-Ras Signaling Pathway

Guénaëlle Levallet, Emmanuel Bergot, Martine Antoine, Christian Creveuil, Adriana O. Santos, Michelle Beau-Faller, Florence de Fraipont, Elisabeth Brambilla, Jérôme Levallet, Franck Morin, Virginie Westeel, Marie Wislez, Elisabeth Quoix, Didier Debieuvre, Fatéméh Dubois, Isabelle Rouquette, Jean-Louis Pujol, Denis Moro-Sibilot, Jacques Camonis and Gérard Zalcman

Mol Cancer Ther May 1 2012 11 (5) 1203-1213; DOI:10.1158/1535-7163.MCT-11-0899

Retraction

Retraction

Retraction in Part: A Genomic Approach to Identify Molecular Pathways Associated with Chemotherapy Resistance

Mol Cancer Ther May 1 2012 11 (5) 1214-1215; DOI:10.1158/1535-7163.MCT-12-0210

Correction

Correction

Correction: Narciclasine, a Plant Growth Modulator, Activates Rho and Stress Fibers in Glioblastoma Cells

Mol Cancer Ther May 1 2012 11 (5) 1216-1217; DOI:10.1158/1535-7163.MCT-12-0327

Main menu

User menu

Search

Table of Contents

Highlights

Reviews

Therapeutic Discovery

Preclinical Development

Molecular Medicine in Practice

Retraction

Correction

Issue Highlights

Jump to

Articles

Info for

About MCT